Virobay

2006 – Founded as a protease inhibitor drug discovery and development company

2007 – Filed IND and initiated Phase I trial with lead protease inhibitor as an oral treatment for Hepatitis C

2007 – In-licensed cathepsin protease inhibitor assets; including VBY-129, a selective cathepsin S inhibitor which completed phase 1 clinical development

2008 – Virobay assets solve the chemical challenge of cathepsin inhibitor design; multiple orally bioavailable development candidates are poised for Phase I

2010 – Virobay closes Series B financing

Learn more